Phosphocreatine disodium

Synonyms: 磷酸胍酸钠; Disodium creatine phosphate
Phosphocreatine (disodium) 是一种存在于脊椎动物骨骼肌中的有机化合物,它通过增强抗氧化活性、激活 TAK1 通路来保护心脏,通过 Akt 介导的 Nrf2/HO-1 途径使线粒体功能正常化并减少氧化应激,并通过 ERK 介导的 Nrf-2/HO-1 途径抑制细胞凋亡 (Apoptosis) 和 ROS (Reactive Oxygen Species) 的产生,从而保护肾脏。
产品编号: MS-L81627 纯度: 98.0% CAS No.: 922-32-7 分子式: C4H8N3Na2O5P 分子量: 255.08
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in Water
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Phosphocreatine (disodium) 是一种存在于脊椎动物骨骼肌中的有机化合物,它通过增强抗氧化活性、激活 TAK1 通路来保护心脏,通过 Akt 介导的 Nrf2/HO-1 途径使线粒体功能正常化并减少氧化应激,并通过 ERK 介导的 Nrf-2/HO-1 途径抑制细胞凋亡 (Apoptosis) 和 ROS (Reactive Oxygen Species) 的产生,从而保护肾脏。

生物实验数据

生物活性 Phosphocreatine (disodium) is an organic compound found in the skeletal muscle of vertebrates that protects the heart by enhancing antioxidant activity and activating the TAK1 pathway, normalizes mitochondrial function and reduces oxidative stress via the Akt-mediated Nrf2/HO-1 pathway, and protects the kidney by inhibiting apoptosis and ROS (Reactive Oxygen Species) production through the ERK-mediated Nrf-2/HO-1 pathway.
IC50 & Target

Human Endogenous Metabolite

 

体外研究
(In Vitro)

非盐形式:
Phosphocreatine (0-1 mM, 24 h) 通过靶向 TAK1 揭示了抗氧化、抗凋亡和抗坏死性凋亡的作用,以保护 H9c2 细胞免受 DOX (Doxorubicin) (HY-15142A) 诱导的心肌细胞损伤。
Phosphocreatine (0-1 mM, 24 h) 通过增加抗氧化活性来缓解氧化应激,随后将 TAK1 的表达水平恢复到基线水平,并减少 DOX 诱导的心肌损伤中的细胞凋亡和程序性死亡。
Phosphocreatine (5-20 mM, 24 h) 可减轻 MGO (Methylglyoxal) (MS-L54006) 诱导的 PC12 细胞损伤和抑制 PC-12 细胞凋亡。
Phosphocreatine (5-20 mM, 24 h) 可防止 MGO (Methylglyoxal) 诱导损伤的 PC-12 细胞线粒体膜通透性丧失。
Phosphocreatine (5-20 mM, 2 h) 对 PC-12 细胞的神经保护作用依赖于通过 Akt 介导的 Nrf2/HO- 1途径使线粒体功能正常化和减少氧化应激。
Phosphocreatine (5-40 mM, 24 h) 在不同浓度下可能有助于保护 NRK-52E 细胞免受 MGO 诱导的肾损伤。
Phosphocreatine (10-40 mM, 4 h) 抑制肾脏氧化应激代谢物。

Apoptosis Analysis

Cell Line: PC-12, NRK-52E cells
Concentration: 5, 10, 20, 40 mM
Incubation Time: 2 h
Result: Significantly suppressed the enhanced early apoptosis in PC-12 cells in a dose-dependent manner.
Increased the expression of Bcl-2, procaspase-3 and procaspase-9 in NRK-52E cells.
Decreased the expression of Bax and cleaved caspase-3 in NRK-52E cells.
Suppressed karyorrhexis and karyopyknosis in NRK-52E cells.
Decreased the apoptotic rate compared with MGO-treated cells in NRK-52E cells.
Prevented the losing of MMP (mitochondrial membrane potential) in NRK-52E cells.

Cell Viability Assay

Cell Line: PC-12, NRK-52E cells
Concentration: 0, 5, 10, 20, 40 mM
Incubation Time: 24 h
Result: Was not toxic to PC-12 cells under the treatment conditions.
Significantly increased PC-12 cell viability at the concentrations of 5, 10 and 20 mM compared with MGO (Methylglyoxal) (MS-L54006) groups.
Contributed to protection of the NRK-52E cells against MGO-induced kidney injury.

Western Blot Analysis

Cell Line: PC-12, NRK-52E cells
Concentration: 20, 40 mM
Incubation Time: 24 h
Result: Increased the expression levels of Akt, Nrf2 (nuclear factor (erythroid-derived-2)-like 2 (Nrf2)) and HO-1 (Hemeoxygenase-1) in PC12 cells.
Increased the expression of nuclear Nrf2 levels, and decreased Nrf2 level in PC12 cells cytoplasm.
Increased the expression of p-Akt, HO-1 and Nrf2 with compared with pre-treatment for 2 h with LY294002 (a PI3K inhibitor) in PC12 cells.
Significantly increased Bcl-2 and procaspase-9 levels and decreased Bax, cleaved caspase-9 and cleaved caspase-3 C level in NRK-52E cells.
Decreased the expression of p-ERK and increased the Nrf2 and HO-1 expressions in NRK-52E cells.
体内研究
(In Vivo)

非盐形式:
Phosphocreatine (200 mg/kg, i.p., 每隔一天一次, 7 周) 不仅减轻了氧化应激和心肌细胞凋亡,而且挽救了 DOX 诱导的大鼠心脏毒性中的心肌坏死。
Phosphocreatine (20-40 mg/kg, i.v., 每天, 6 周) 对 SD (Sprague-Dawley) 大鼠的肾组织具有保护作用,可预防糖尿病肾病。

Animal Model: Male Sprague Dawley (SD) rats, i.p., normal saline, 3 times; i.p., DOX 2 mg/kg, 7 times; i.p., normal saline, 3 times
Dosage: 200 mg/kg
Administration: i.p., once every other day, 7 weeks
Result: Improved the heart function abnormality.
Lowered myocardial apoptosis.
Recovered the expression of Nrf2, SOD, FoxO3a and diminished C-Casp3, Bax/Bcl2 in the myocardial tissue of rats.
Markedly improved myocardial necroptosis, as indicated by decreasing expression of RIP3 and CaMKII.
Increased expression level of TAK1.
Animal Model: Male Sprague Dawley (SD) rats, i.p., 70 mg/kg (STZ(Streptozotocin) (MS-Q80520)), daily, 6 weeks
Dosage: 20, 40 mg/kg
Administration: i.p., daily, 6 weeks
Result: Reduced hyperglycemia compared with STZ (Streptozotocin) (MS-Q80520) -treated rats.
Increased the weight of rats gradually compared with STZ (Streptozotocin) (MS-Q80520) group.
Decreased kidney weight index (kidney weight/body weight).
Decreased MDA level and increased of GSH and SOD levels compared with STZ group.
Decreased the apoptotic rate compared with MGO-treated groups.
性状 固体
颜色 White to off-white

化学信息

分子量 255.08
分子式 C4H8N3Na2O5P
CAS No. 922-32-7
别名 磷酸胍酸钠; Disodium creatine phosphate

储存&溶解度

储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 125 mg/mL (490.04 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM3.9203 mL19.6017 mL39.2034 mL98.0085 mL
5 mM0.7841 mL3.9203 mL7.8407 mL19.6017 mL
10 mM0.3920 mL1.9602 mL3.9203 mL9.8008 mL
15 mM0.2614 mL1.3068 mL2.6136 mL6.5339 mL
20 mM0.1960 mL0.9801 mL1.9602 mL4.9004 mL
25 mM0.1568 mL0.7841 mL1.5681 mL3.9203 mL
30 mM0.1307 mL0.6534 mL1.3068 mL3.2669 mL
40 mM0.0980 mL0.4900 mL0.9801 mL2.4502 mL
50 mM0.0784 mL0.3920 mL0.7841 mL1.9602 mL
60 mM0.0653 mL0.3267 mL0.6534 mL1.6335 mL
80 mM0.0490 mL0.2450 mL0.4900 mL1.2251 mL
100 mM0.0392 mL0.1960 mL0.3920 mL0.9801 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础